Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.79 ($0.04), with a volume of 1444862 shares changing hands. The stock had previously closed at GBX 2.85 ($0.04).
Wall Street Analyst Weigh In
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, January 2nd.
View Our Latest Report on POLB
Poolbeg Pharma Stock Up 1.8 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- Technology Stocks Explained: Here’s What to Know About Tech
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- Stock Sentiment Analysis: How it Works
- Top 3 Beverage Stocks Pouring Out Profits
- The 3 Best Fintech Stocks to Buy Now
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
